Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-50 (canceled).

51. (new) A composition comprising a chemotherapeutic agent and a conjugate of a CD44v6 specific antibody molecule and a maytansinoid.

52. (new) The composition of claim 51, wherein the antibody molecule is specific for an epitope within the amino acid sequence SEQ ID NO:3.

53. (new) The composition of claim 52, wherein the antibody molecule is the monoclonal antibody VFF-18 (DSM ACC2174) or a recombinant antibody having the complementary determining regions (CDRs) of VFF-18.

54. (new) The composition of claim 53, wherein the antibody molecule comprises light chains having the amino acid sequence SEQ ID NO:4, or SEQ ID NO:8, and heavy chains having the amino acid sequence SEQ ID NO:6.

55. (new) The composition of claim 54, wherein the maytansinoid is linked to the antibody molecule by a disulfide moiety.

56. (new) The composition of claim 55, wherein the maytansinoid has the formula:



Formula (IV).

57. (new) The composition of claim 51, wherein the chemotherapeutic agent is a tubulin binding agent.

58. (new) The composition of claim 51, wherein the chemotherapeutic agent is a microtubule stabilizing agent.

59. (new) The composition of claim 51, wherein the chemotherapeutic agent is a taxane or an epothilone.

60. (new) The composition of claim 51, wherein the chemotherapeutic agent is paclitaxel, docetaxel, RPR-116258A, epothilone A, B, C, D, E, or F, BMS-247550, or BMS-310705.

61. (new) The composition of claim 51, wherein the chemotherapeutic agent is a microtubule destabilizing agent.

62. (new) The composition of claim 51, wherein the chemotherapeutic agent is a vinca alkaloid.

63. (new) The composition of claim 51, wherein the chemotherapeutic agent is vinblastine, vincristine, vinflunine, vindesine, navelbine, or vinorelbine.

64. (new) The composition of claim 51, wherein the chemotherapeutic agent is a taxane, an epothilone, a vinca alcaloid, a platinum compound, a camptothecin, a cryptophycin, a dolastatin, a 5,6-dihydroindolo[2,1-a]isoquinoline derivative, a spongistatin, an epipodophyllotoxin, an alkylating agent, an purine antagonist, a pyrimidine antagonist, or a DNA intercalator.

65. (new) The composition of claim 51, wherein the chemotherapeutic agent is docetaxel, paclitaxel, RPR-116258A, epothilone A, B, C, D, E, or F, BMS-247550, BMS-310705, vinblastine, vindesine, vincristine, vinorelbine, vinflunine, navelbine, combretastatin A4-phosphate, hydroxphenastatin, AVE 8062, spongistatin 1, 2, 3, 4, 5, 6, 7, 8, or 9, E-7010, dolastatin, cemadotin

hydrochloride, mivobulin isethionate, cryptophycin, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, doxorubicin, daunorubicin, dactinomycin, plicamycin, mitomycin, bleomycin, idarubicin, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, procarbazine, dacarbazine, altretamine, carmustine, lomustine, semustine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, fluorouracil, capecitabine, cytarabine, or azacytidine.

66. (new) A method of treating cancer comprising administering a compound comprising a conjugate of a CD44v6 specific antibody molecule and a maytansinoid in combination with a chemotherapeutic agent.

67. (new) The method of claim 66, wherein the chemotherapeutic agent is a tubulin binding agent.

68. (new) The method of claim 66, wherein the chemotherapeutic agent is a microtubule stabilizing agent.

69. (new) The method of claim 66, wherein the chemotherapeutic agent is a taxane or an epothilone.

70. (new) The method of claim 66, wherein the chemotherapeutic agent is paclitaxel, docetaxel, RPR-116258A, epothilone A, B, C, D, E, or F, BMS-247550, or BMS-310705.

71. (new) The method of claim 66, wherein the chemotherapeutic agent is a microtubule destabilizing agent.

72. (new) The method of claim 66, wherein the chemotherapeutic agent is a vinca alkaloid.

73. (new) The method of claim 66, wherein the chemotherapeutic agent is vinblastine, vincristine, vinflunine, vindesine, navelbine, or vinorelbine.

74. (new) The method of claim 66, wherein the chemotherapeutic agent is a taxane, an epothilone, a vinca alcaloid, a platinum compound, a camptothecin, a cryptophycin, a dolastatin, a 5,6-dihydroindolo[2,1-a]isoquinoline derivative, a spongistatin, an epipodophyllotoxin, an alkylating agent, a purine antagonist, a pyrimidine antagonist, or a DNA intercalator.

75. (new) The method of claim 66, wherein the chemotherapeutic agent is docetaxel, paclitaxel, RPR-116258A, epothilone A, B, C, D, E, or F, BMS-247550, BMS-310705, vinblastine, vindesine, vincristine, vinorelbine, vinflunine, navelbine, combretastatin A4-phosphate, hydroxphenastatin, AVE 8062, spongistatin 1, 2, 3, 4, 5, 6, 7, 8, or 9, E-7010, dolastatin, cemadotin hydrochloride, mivobulin isethionate, cryptophycin, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, doxorubicin, daunorubicin, dactinomycin, plicamycin, mitomycin, bleomycin, idarubicin, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, procarbazine, dacarbazine, altretamine, carmustine, lomustine, semustine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, fluorouracil, capecitabine, cytarabine, or azacytidine.

76. (new) The method of claim 66, wherein the antibody molecule is specific for an epitope within the amino acid sequence SEQ ID NO:3.

77. (new) The method of claim 66, wherein the antibody molecule is the monoclonal antibody VFF-18 (DSM ACC2174) or a recombinant antibody having the complementary determining regions (CDRs) of VFF-18.

78. (new) The method of claim 66, wherein the antibody molecule comprises light chains having the amino acid sequence SEQ ID NO:4 or SEQ ID NO:8, and heavy chains having the amino acid sequence SEQ ID NO:6.

79. (new) The method of claim 66, wherein the maytansinoid is linked to the antibody molecule by a disulfide moiety.

80. (new) The method of claim 66, wherein the maytansinoid has the formula:



Formula (IV).

81. (new) The method of claim 66, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, esophagus squamous cell carcinoma, lung squamous cell carcinoma, skin squamous cell carcinoma, cervix squamous cell carcinoma, breast adenocarcinoma, lung adenocarcinoma, pancreas adenocarcinoma, colon adenocarcinoma, and stomach adenocarcinoma.

82. (new) The method of claim 66, wherein said conjugate and said chemotherapeutic agent are formulated in separate pharmaceutical compositions.

83. (new) The method of claim 66, wherein said conjugate and said chemotherapeutic agent are formulated in one single pharmaceutical composition.

84. (new) A method for treating cancer comprising administering a compound comprising a conjugate of a CD44v6 specific antibody molecule and a maytansinoid in combination with a chemotherapeutic agent, wherein said antibody molecule comprises light chains having the amino acid sequence SEQ ID NO:4 and heavy chains having the amino acid sequence SEQ ID NO:6, and wherein the maytansinoid has the formula:



Formula (IV),

and is linked to the antibody through a disulfide bond.

85. (new) The method of claim 84, wherein one or more maytansinoid residues are linked to an antibody molecule.

86. (new) The method of claim 84, wherein 3 to 4 maytansinoid residues are linked to an antibody molecule.

87. (new) The method of claim 84, wherein the maytansinoid is linked to the antibody molecule through a $-S-CH_2CH_2-CO-$, a $-S-CH_2CH_2CH_2CH_2-CO-$, or a $-S-CH(CH_3)CH_2CH_2-CO-$ group.

88. (new) The method of claim 84, wherein the chemotherapeutic agent is a tubulin binding agent.

89. (new) The method of claim 84, wherein the chemotherapeutic agent is a microtubule stabilizing agent.

90. (new) The method of claim 84, wherein the chemotherapeutic agent is a taxane or an epothilone.

91. (new) The method of claim 69, wherein the chemotherapeutic agent is paclitaxel, docetaxel, RPR-116258A, BMS-247550, BMS- 310705, or epothilone A, B, C, D, E, or F.

92. (new) The method of claim 84, wherein the chemotherapeutic agent is a microtubule destabilizing agent.

93. (new) The method of claim 84, wherein the chemotherapeutic agent is a vinca alkaloid.

94. (new) The method of claim 84, wherein the chemotherapeutic agent is vinblastine, vincristine, vindesine, vinflunine, navelbine, or vinorelbine.

95. (new) The method of claim 84, wherein the chemotherapeutic agent is a taxane, an epothilone, a vinca alcaloid, a platinum compound, a camptothecin, a cryptophycin, a dolastatin, a 5,6-dihydroindolo[2,1-a]isoquinoline derivative, a spongistatin, an epipodophyllotoxin, an alkylating agent, a purine antagonist, a pyrimidine antagonist, or a DNA intercalator.

96. (new) The method of claim 84, wherein the chemotherapeutic agent is docetaxel, paclitaxel, RPR-116258A, epothilone A, B, C, D, E, or F, BMS-247550, BMS-310705, vinblastine, vindesine, vincristine, vinorelbine, vinflunine, navelbine, combretastatin A4-phosphate, hydroxphenastatin, AVE 8062, spongistatin 1, 2, 3, 4, 5, 6, 7, 8, or 9, E-7010, dolastatin, cemadotin hydrochloride, mivobulin isethionate, cryptophycin, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, doxorubicin, daunorubicin, dactinomycin, plicamycin, mitomycin, bleomycin, idarubicin, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, procarbazine, dacarbazine, altretamine, carmustine, lomustine, semustine, methotrexate, mercaptopurine, thioguanine, fludarabine phosphate, cladribine, pentostatin, fluorouracil, capecitabine, cytarabine, or azacytidine.

97. (new) The method of claim 84, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, esophagus squamous cell carcinoma, lung squamous cell carcinoma, skin squamous cell carcinoma, cervix squamous cell carcinoma, breast adenocarcinoma, lung adenocarcinoma, pancreas adenocarcinoma, colon adenocarcinoma, or stomach adenocarcinoma.

98. (new) The method of claim 84, wherein said conjugate and said chemotherapeutic agent are formulated in separate pharmaceutical compositions.

99. (new) The method of claim 84, wherein said conjugate and said chemotherapeutic agent are formulated in one single pharmaceutical composition.